Fairvalue-Calculator Fairvalue-Calculator
EN DE

Zhengye Biotechnology Holding (ZYBT) Fair Value & Analysis

Healthcare · US · Market cap $36.6M

Price$0.7611
Fair Value$0.1600
Upside-79.0%
Quality80/100
Evidence: Medium Range $0.1500 – $0.1700

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Zhengye Biotechnology Holding (ZYBT) currently trades at $0.7611, while our model-based Fair Value estimate is $0.1600 — implying the stock looks roughly 79.0% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

Frequently asked questions

Is Zhengye Biotechnology Holding (ZYBT) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.1600 versus a price of $0.7611 — about −79% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ZYBT?
Our 21-model fair value for Zhengye Biotechnology Holding is $0.1600 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.7611.
What is the quality score of ZYBT?
Zhengye Biotechnology Holding has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.